Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business asset acquisition

Novartis India acquires Pfizer Minipress trademarks

Analysis based on 7 articles · First reported Sep 07, 2026 · Last updated Sep 07, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The acquisition strengthens Novartis's cardiovascular portfolio and is expected to contribute incremental revenue, supporting its growth under new private-equity ownership. Pfizer's exit from the product in India reflects a strategic divestiture, with a one-time payment offsetting the discontinuation.

Pharmaceuticals

On September 7, 2026, Novartis announced the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with related intellectual property rights, from Pfizer and Pfizer — Pfizer Products Inc. for a total consideration of approximately ₹1,250 crore. The transaction was approved by Novartis's board and executed through an asset purchase agreement and trademark assignment deeds, with signing and closing occurring simultaneously. Minipress XL, containing prazosin, is used to treat hypertension and manage urinary symptoms of benign prostatic hyperplasia. According to IQVIA MAT July 2026 data, Minipress XL recorded revenue of ₹228.6 crore, growing at a CAGR of 6.3% over four years. Concurrently, Pfizer announced it would discontinue marketing, distribution, and sale of Minipress XL in India effective September 7, 2026, following Pfizer's decision to stop manufacturing the product. Pfizer will receive a lump-sum payment of $13.9 million (approximately ₹131.38 crore) from Pfizer USA. The acquisition follows ChrysCapital's acquisition of a 70.68% stake in Novartis from Novartis, and comes after Abbott Laboratories terminated its distribution agreement with Novartis for select brands, effective until September 30, 2026. Novartis shares rose 2.9% to ₹1,683.35 on the BSE, while Pfizer shares fell 0.8% to ₹4,572.70 on the NSE.

100 Novartis acquired trademarks Pfizer
80 Pfizer discontinued sales
70 Pfizer discontinued manufacture
50 Abbott Laboratories terminated agreement Novartis
stock
Acquirer of Minipress trademarks, expanding its cardiovascular portfolio; shares rose 2.9% on the announcement.
Importance 100.0 Sentiment 80.0
stock
Seller of Minipress trademarks and discontinuing manufacture of Minipress XL; receives payment to Pfizer.
Importance 90.0 Sentiment -10.0
subs
Co-seller of the trademarks, transferring rights to Novartis.
Importance 60.0 Sentiment -10.0
priv
Private-equity owner of Novartis, driving portfolio expansion through this acquisition.
Importance 50.0 Sentiment 60.0
stock
Terminated distribution agreement with Novartis for select brands, continuing commercialization until September 30, 2026.
Importance 40.0 Sentiment 0.0
cnt
Market where the trademarks are registered and where the transaction impacts pharmaceutical competition.
Importance 40.0 Sentiment 20.0
cnt
Home country of Pfizer entities involved in the transaction.
Importance 20.0 Sentiment 0.0
stock
Provided market data on Minipress XL revenue and growth cited in the announcement.
Importance 20.0 Sentiment 0.0
exch
Exchange where Novartis shares are listed and traded.
Importance 10.0 Sentiment 0.0
exch
Exchange where Pfizer shares are listed and traded.
Importance 10.0 Sentiment 0.0
Novartis related ↔ United States
Pfizer related ↔ India
Pfizer related ↔ United States
India strategic partners ↔ United States India views the United States as a key strategic and economic partner, engaging in defense cooperation and significant t
India related ↔ JSE Limited
United States related ↔ IQVIA
JSE Limited peer exchange ↔ National Stock Exchange of India JSE Limited and National Stock Exchange of India are independent stock exchanges operating in different geographical mar
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.